O ver the past 2 decades, the discovery of congenital and acquired (typically drug-induced) long QT syndrome (LQTS)-causative variation in genes that encode components of cardiac ion channel macromolecular complexes and intracellular calcium-handling proteins provided an impetus for the development and refinement of clinical genetic tests for LQTS. 1, 2 Bolstered by clinically relevant genotype-phenotype correlations and gene-specific risk-stratification and risk-management strategies, 3 LQTS genetic testing has evolved in the last decade from initial research laboratory-based endeavors to the current range of clinically useful, commercially available, and reimbursable genetic tests. 4 However, the emergence of next-generation sequencing technologies and ensuing large-scale sequencing efforts has exposed an unexpectedly high frequency of genetic variation within many Mendelian disease-susceptibility genes. Both the canonical and minor LQTS-susceptibility genes are no exception, and alarms about genetic noise were first sounded in 2003. 5, 6 Rare nonsynonymous variants in the 3 primary LQTS-susceptibility genes (KCNQ1, KCNH2, and SCN5A) are seen in ≈3% to 8% of individuals and make assignment of causation problematic. [7] [8] [9] Interpretation of genetic variants in the 14 minor LQTS-susceptibility genes, for which fewer data on functional consequences are available, is correspondingly more difficult. 5, 6, [10] [11] [12] In an effort to add clarity and uniformity to the classification and reporting of genetic variants in LQTS and other Mendelian disorders, the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) released a new set of interpretation and reporting standards in 2015. 13 These standards have provided a much-needed framework for clinical molecular laboratories tasked with assessing the pathogenicity of putative diseasecausative variants identified in patients with suspected Mendelian disorders. However, the current ACMG/AMP standards specifically avoid guidance on how common genetic variants that may modify the phenotypic manifestations of Mendelian diseases should be classified and incorporated into diagnostic reports. Such variants have minor allele frequencies (MAFs) that far exceed disease prevalence and thus cannot be designated as fully penetrant disease-causing for uncommon monogenic disorders. However, for some of these variants, there is extensive functional and epidemiological evidence to support a role in the modification of disease expressivity or the ability to function as independent primary disease-causative alleles under certain conditions. Unfortunately, due to the current interpretation (or misinterpretation) of the 2015 ACMG/AMP by clinical genetic testing laboratories, many potentially proarrhythmic but relatively common genetic variants in established LQTS genes are excluded from diagnostic genetic testing reports despite a potential role in clinical decision making.
In light of this pressing issue, this white paper utilizes LQTS as a prototype to (1) examine the conundrum created by the failure of prevailing paradigms to provide adequate guidance regarding the classification and reporting of common genetic variants that may impact clinical decision making, and (2) investigate potential mechanisms by which current ACMG/AMP standards could be modified to better facilitate reporting of these variants in hopes that future genetic testing reports more accurately reflect true genetic risk without introducing additional sources of diagnostic miscues.
CLASSIFICATION AND REPORTING OF POTENTIALLY PROARRHYTHMIC COMMON VARIANTS: THE CASE OF P.SER1103TYR-SCN5A AND P.ASP85ASN-KCNE1
Because of the profound heterogeneity observed with the reporting and classification of variants, 14 the ACMG/AMP developed the 2015 variant classification and reporting standards to address challenges associated with the increased utilization of next-generation sequencing and inconsistencies in interlaboratory variant classification. 13 In response, many laboratories, including commercial genetic testing companies, that perform clinical genetic testing for Mendelian disorders voluntarily revised their variant classification and reporting schemes to align with the ACMG/AMP guidelines (Table 1) . [15] [16] [17] [18] [19] It is important to note that the 2015 ACMG/AMP guidelines do not state explicitly that variants classified as benign or likely benign should be excluded from diagnostic genetic testing reports. In fact, narrative sections for benign and likely benign variants are even included in sample reports provided by the ACMG/AMP. However, the majority of commercial genetic testing companies have elected to exclude benign and likely benign variants from their clinical reports (Table 1) . Unfortunately, this includes common variants with functionally and clinically significant proarrhythmic potential that do not fit cleanly into 1 of the 5 ACMG/AMP variant classification categories and often receive a benign or likely benign designation based largely on MAF. Consequently and currently, unless ordering healthcare providers specifically request to be informed of the benign and likely benign variants present in their patients, they will never know whether a relatively common but potentially clinically informative common genetic variant is present. As such, the presence of such variants is being withheld from both the patient and physician who ordered the genetic test. In an effort to ascertain whether relatively common genetic 621 Common Variant Reporting in Long QT Syndrome Genetic Testing variants with the potential to influence clinical decision making in LQTS and other Mendelian disorders are missing in action because of current variant classification and reporting practices or are no longer clinically actionable secondary to a lack of supporting epidemiological or functional evidence, the following paragraphs examine the case for inclusion of 2 well-studied common variants (p.Ser1103Tyr-SCN5A and p.Asp85Asn-KCNE1) in diagnostic LQTS genetic testing reports.
p.Ser1103Tyr-SCN5A: Background Noise or Potentially Proarrhythmic Common Variant in Individuals of African Descent?
In individuals of African descent, the common SCN5A-encoded Na v 1.5 sodium channel variant p.Ser1103Tyr-SCN5A, found in ≈10% of blacks, has been associated with baseline heart-rate corrected QT interval (QTc) prolongation and a small but persistent risk of arrhythmia/sudden cardiac death (SCD) across the age spectrum. [20] [21] [22] [23] [24] [25] Furthermore, in vitro functional characterization by 2 independent groups demonstrated that p.Ser1103Tyr-SCN5A accentuates the sustained/late sodium current comparable to the electrophysiological phenotype displayed by LQT3-causative p.L613F-SCN5A and p.delQKP1507-1509-SCN5A pathogenic variants. 20, 23, 26, 27 However, neither study demonstrated an in vitro or in silico ability of p.Ser1103Tyr-SCN5A to prolong action potential duration in the absence of a second hit, such as pharmacological blockade of the rapid component of the delayed rectifier potassium current or respiratory/metabolic acidosis that may arise in the setting of common comorbid conditions, such as sleep apnea, congestive heart failure, and chronic kidney disease.
Clinically, this epidemiological and functional evidence suggests that p.Ser1103Tyr-SCN5A is capable of creating a circumstance-dependent, proarrhythmic state that may lead to (1) sudden infant death syndrome in vulnerable black infants, 23, 24 and (2) potentially life-threatening arrhythmias in black adults receiving QT-prolonging/hypokalemia-predisposing medications, 20, 25 as well as those with underlying structural heart disease. 21, 22 p.Asp85Asn-KCNE1: Background Noise or Potentially Proarrhythmic Common Variant in All Genetic Backgrounds?
The p.Asp85Asn-KCNE1 variant, present in ≈1% of individuals worldwide, increases baseline QTc in the general population, [28] [29] [30] confers an increased risk of drug-induced torsades de pointes, 31, 32 modulates the phenotypic severity of primary congenital LQTS (cLQTS)-causative KCNQ1 (LQT1) and KCNH2 (LQT2) pathogenic variants, 33, 34 and serves as a weak/low penetrant cLQTS-causative variant in Japanese subjects. 35 In addition, ≥3 independent groups have demonstrated that p.Asp85Asn-KCNE1 imparts LQTS-like loss of function in vitro through biophysical effects on the rapid and slow components of the phase 3 delayed rectifier repolarizing potassium currents (I K ). 33, 35, 36 Collectively, the modest cumulative reduction in I K associated with p.Asp85Asn-KCNE1 appears capable of creating a circumstance-dependent, proarrhythmic state in the presence of a second hit, such as (1) the use of QTcprolonging medications, 31, 32 (2) a repolarization reservedeficient genetic background caused by a primary LQTS pathogenic variant, 33, 34 or (3) in rare cases, a genetic cocktail of multiple common QTc-prolonging genetic variants. Although p.Ser1103Tyr-SCN5A and p.Asp85Asn-KCNE1 both fail to meet ACMG/AMP criteria for adjudication as cLQTS-causative pathogenic variants ( Figure 1 ), 13 in the context of the epidemiological and functional evidence summarized in Table 2 , 20, 23, 31, 33, 35, 36 it is somewhat surprising that the majority of clinical laboratories, including several commercial genetic testing companies contributing voluntarily to the National Center for Biotechnology's Clinical Variant database, 15 adjudicate p.Ser1103Tyr-SCN5A and p.Asp85Asn-KC-NE1 as benign or likely benign (Table 1) .
On closer inspection, it appears that a failure to consider epidemiological evidence implicating p.Ser1103Tyr-SCN5A and p.Asp85Asn-KCNE1 in the pathogenesis of acquired/drug-induced long QT syndrome (aLQTS) at least partially explains this discrepancy. Given that subclinical/concealed cLQTS is often unmasked by nongenetic aLQTS risk factors (ie, electrolyte abnormalities, QTc-prolonging drugs, etc) and a small subset of patients with drug-induced aLQTS harbors cLQTS-causative pathogenic variants, 32, 37, 38 the clinical and genetic overlap between aLQTS and cLQTS merits consideration during LQTS variant adjudication. As such, we readjudicated p.Ser1103Tyr-SCN5A and p.Asp85Asn-KCNE1 in light of additional epidemiological evidence supporting a role for these variants in aLQTS and SCD susceptibility (Figure 1b and 1c) . Reclassification of these variants in the context of evidence supporting a role in both aLQTS and cLQTS resulted in a variant of uncertain significance designation that would likely result in the inclusion of p.Ser1103Tyr-SCN5A and p.Asp85Asn-KCNE1 on commercial LQTS genetic testing reports (Figure 1b and  1c) . However, even a variant of uncertain significance designation fails to convey the true risk associated with p.Ser1103Tyr-SCN5A and p.Asp85Asn-KCNE1 to the ordering healthcare professional. This is particularly problematic for SCD-predisposing conditions in which the clinical context at the time of a patient's sentinel cardiac event may never be completely understood (ie, electrolyte derangements, QTcprolonging medication use, etc). As such, ordering healthcare professionals deserve to receive as robust a genetic risk profile as possible, including the presence of potentially proarrhythmic common variants such as p.Ser1103Tyr-SCN5A and p.Asp85Asn-KCNE1 with the capability to mimic the clinical sequelae of rare cLQTScausative pathogenic variants under certain conditions. Armed with this genetic information, ordering physicians can then determine whether a given patient's clinical picture can be explained, in whole or in part, by a perfect storm involving the combination of nongenetic risk factors and common variants with proarrhythmic potential, such as p.Ser1103Tyr-SCN5A and p.Asp85Asn-KCNE1.
Unfortunately, even if broader epidemiological evidence is used to adjudicate p.Ser1103Tyr-SCN5A and p.Asp85Asn-KCNE1, the current ACMG/AMP framework does not contain a provision that allows for the accurate classification and reporting of potentially proarrhythmic common variants. As such, the current ACMG/ AMP variant classification and reporting standards need to be amended urgently to provide a mechanism to (1) differentiate common variants such as p.Ser1103Tyr-SC-N5A and p.Asp85Asn-KCNE1 with epidemiological and functional evidence to suggest a conditional pathogenic contribution from truly ambiguous variants of uncertain significance and benign variants, and (2) encourage the reporting of common variants with the potential to impact clinical decision making in a standardized fashion that minimizes the risk of misinterpretation and potential diagnostic miscues.
FUNCTIONAL RISK ALLELE: A NECESSARY ADDITION TO EXISTING ACMG/AMP VARIANT CLASSIFICATION AND REPORTING STANDARDS?
Although current ACMG/AMP guidelines provide little guidance regarding the classification and report of common variants that may contribute to the pathogen- aLQTS indicates acquired/drug-induced long QT syndrome; cLQTS, congenital long QT syndrome; dbSNP ID, single-nucleotide polymorphism database identification; ExAC, Exome Aggregation Consortium; I Kr , rapid component of the delayed-rectifier potassium current; I Ks , slow component of the delayed-rectifier potassium current; I Na , inward depolarizing sodium current; MAF, minor allele frequency; and QTc, heart-rate corrected QT interval.
*Odds ratio calculated from case and control MAFs provided within the original article by Nishio et al. 35 esis of Mendelian disorders under certain conditions, they do recommend the reporting of alleles associated with complex/polygenic disease identified incidentally throughout the course of Mendelian disorder genetic testing as risk alleles within a distinct "Other Reportable" category. 13 Because both p.Ser1103Tyr-SCN5A and p.Asp85Asn-KCNE1 underlie QTc duration variability in population-based or genome-wide association studies, 28 ,39,40 they would both technically qualify for classification as established/likely risk alleles under this provision of the 2015 ACMG/AMP guidelines. 13 However, a positive genome-wide association, regardless of the odds ratio/effect size, should not be confused with clinical utility or actionability. In fact, reporting of the ≈70 common genetic variants associated with small independent effects on QTc 40 in the general population would (1) be onerous for genetic testing companies, (2) clutter excessively LQTS genetic testing reports, and (3) be impossible for healthcare professionals to interpret. Therefore, only those common variants with multiple lines of evidence (ie, ACMG pathogenic criteria such as an odds ratio >5 in multiple case-control studies, well-established functional evidence, etc) to support a potential conditional contribution to Mendelian disease pathogenesis merit consideration for inclusion on genetic test reports.
One potential interim solution to this conundrum is to create separate risk allele and functional risk allele designations using criteria within the current ACMG/ AMP framework (Table 3) . Under these new designations, common and uncommon variants whose MAFs argue against pathogenicity in isolation but with strong epidemiological (ie, an odds ratio >5 in casecontrol studies consistent with existing pathogenic ACMG/AMP criteria) to suggest a potential pathogenic contribution under certain circumstances are designated as risk alleles (Table 3) . Furthermore, variants such as p.Ser1103Tyr-SCN5A and p.Asp85Asn-KCNE1, which satisfy risk allele criteria and for which well-established functional studies display a deleterious effect on gene (ie, splicing efficiency, transcriptional/translational efficiency, etc) or protein function (ie, heterologous expression, in vivo model systems, patient-specific-induced pluripotent stem cells, etc), are eligible for elevation to the designation of functional risk allele in general and, in the context of heritable cardiac arrhythmia syndrome genetic testing, a potentially proarrhythmic functional risk allele (Table 3) . Last, because of ethnic-specific genetic backgrounds, use of divergent in vivo model organisms, or variable in vitro experimental conditions, as illustrated above, circumstances are bound to arise in which discrepant epidemiological or functional evidence exists for a given genetic variant. Unfortunately, no formal guidelines exist to help variant adjudicators or ordering healthcare professionals resolve discrepant clinical or functional data. However, in the event that discrepancies cannot be readily explained (eg, variable accessory subunit coexpression, established difference in endogenous/background current expression between cell lines, etc), the use of a third designation-possible risk allele-weak/conflicting evidence-can be considered to alert ordering healthcare professionals to the presence of a relatively common variant with some evidence, albeit weak, to suggest that the variant may not be completely benign. Regardless of designation, to avoid potentially harmful diagnostic miscues, variants meeting these criteria should be reported under a separate Risk Allele or Other Reportable category with a boilerplate disclaimer such as, "This variant is not a self-sufficient, disease-causative mutation in isolation. However, in the setting of either diseasecausative mutations or acquired risk factors, the presence of this risk allele can potentially increase the patient's risk of disease."
As applied to relatively common amino acid-altering variants in major channelopathy-susceptibility genes likely to be encountered in clinical practice ( Table 4) 41-63 and outlined in Figure 2 , 64 this classification scheme provides a mechanism to bring potentially clinically meaningful variants, including p.Ser1103Tyr-SCN5A and p.Asp85Asn-KCNE1, which might otherwise be ignored or perpetually stuck erroneously with a variant of uncertain significance designation, to the attention of ordering healthcare professionals. Unfortunately, because of a reliance on existing ACMG/AMP criteria, these designations are anticipated to be overly conservative and fail to account for (1) established channelopathy-associated genetic modifiers such as p.His558Arg-SCN5A, which may confer either a protective or deleterious effect on the phenotypic severity associated with a primary disease-causative pathogenic variant; (2) composite effect(s) of >1 relatively com- mon genetic variants, such as p.Ala572Asp-SCN5A plus p.His558Arg-SCN5A or p.Val1951Leu-SCN5A with p.delGln1077-SCN5A (Table 4) , which produce a synergistic effect under a specific genomic context (ie, on the same [cis] or on the opposite allele [trans] relative to each other); (3) the underappreciated ability of coding region variants to impact gene function/expression independent of protein-level effects (ie, codon bias influencing translational efficiency, epigenetic regulation, splicing efficiency, etc); and (4) variants that reside outside protein-coding regions and canonical splice sites. This is because of the lack of criteria within the existing ACMG/AMP guidelines to account for these issues and represents an area where future disease-specific guidelines could improve on the existing ACMG/AMP variant classification standards. That said, inclusion of potentially proarrhythmic common variants such as p.Ser1103Tyr-SCN5A and p.Asp85Asn-KCNE1 within a distinct category of the genetic testing report would allow for the communication of variants that may influence clinical decision making without increasing the risk of diagnostic miscues secondary to the mis-or overinterpretation of these findings. When healthcare providers are properly informed of the presence of one of these aforementioned functional risk alleles, avoiding QT-prolonging medications (www.crediblemeds.org) may be a simple and yet life-saving preventative measure. 65 Accordingly, an updated classification scheme with reporting of these risk alleles and functional risk alleles is needed urgently. Such an updated classification scheme could be beneficial in LQTS and other SCD-predisposing cardiac channelopathies decision making (eg, risk stratification, selection of antiarrhythmic drugs, etc) as well as other Mendelian disorders.
BEYOND LONG QT SYNDROME: FUNCTIONAL RISK ALLELES AND NONCHANNELOPATHIC MENDELIAN HEART DISORDERS
As illustrated in Table 2 , the number of risk alleles and functional risk alleles potentially unearthed but not currently reported during the course of genetic testing for LQTS and other SCD-predisposing cardiac channelopathies extends beyond p.Ser1103Tyr-SCN5A and p.Asp85Asn-KCNE1. Given the number of channelopathy/QT interval genome-wide association studies and the relative ease with which the functional impact of nonsynonymous genetic variation in cardiac ion channel genes can be assessed in vitro, these findings should come as little surprise. However, it would be presumptuous to assume that the common variant reporting issue exemplified by p.Ser1103Tyr-SCN5A and p.Asp85Asn-KCNE1 is confined to the cardiac channelopathies.
In fact, evidence already exists to suggest a similar common variant phenomenon may, albeit to a lesser extent, impact nonchannelopathic genetic heart disorders. Within the cardiomyopathies, the strongest example involves a common 25-base pair deletion in intron 32 of MYBPC3, present in ≈4% of South Asians, that leads to exon 33 skipping and increased risk of late-onset hypertrophic cardiomyopathy. 66 Although unlikely to be encountered using the sequencing approaches commonly ACMG indicates American College of Medical Genetics and Genomics; aLQTS, acquired long QT syndrome; BrS, Brugada syndrome; CE, conflicting evidence; ExAC, Exome Aggregation Consortium; GoF, gain of function; ICD, implantable cardioverter-defibrillator; I Kr , rapid component of the delayed-rectifier potassium current; I Ks , slow component of the delayed-rectified potassium current; I Na , inward depolarizing sodium current; LoF, loss of function; LQTS, long QT syndrome; MAF, minor allele frequency; MI, myocardial infarction; N/A, not available; NaV1.5, voltage-gated sodium channel 1.5; PolyPhen2, polymorphism phenotyping version 2; TdP, torsades de pointes; SCD, sudden cardiac death; SHD, structural heart disease; SIDS, sudden infant death syndrome; SIFT, sorting intolerant from tolerant; SQTS, short QT syndrome; and WE, weak evidence.
*The association of a functional phenotype with these variants may be dependent on genomic context (p.Ala572Asp-SCN5A with p.His558Arg, p.Val1951Leu-SCN5A with p.delGln1077-SCN5A, and p.Pro2006Ala-SCN5A with p.His558Arg-SCN5A).
†At a minimum, the authors recommend reporting of these variants under a distinct Risk Allele or Other Reportable category with a disclaimer such as, "This variant is NOT a self-sufficient disease-causative mutation in isolation. However, in the setting of either disease-causative mutations or acquired risk factors, the presence of this particular variant can potentially increase the patient's risk of disease expressivity." ‡At present, there is not substantive epidemiological evidence to support a role for variants classified as possible risk allele-conflicting/weak evidence in clinical decision making. However, should these variants be included in future genetic testing reports (eg, as benign/likely benign variants), every effort should be made to alert ordering healthcare providers of the potential deleterious functional effect(s) associated with these variants and the genomic context, if any, where this deleterious functional effect is most likely to be observed (eg, coexistence of p.Ala572Asp-SCN5A with p.His558Arg-SCN5A).
§Because of limitations associated with the current ACMG/AMP classification criteria, it is anticipated that variants primarily acting as genetic modifiers will continue to be classified as benign/likely benign. Until revised/formal guidelines are available, inclusion of variants such as SCN5A-His558Arg that primarily act as modifiers should be evaluated on a case-by-case basis and potentially listed as "possible genetic modifiers if substantive evidence exists to support such a role." Common Variant Reporting in Long QT Syndrome Genetic Testing used in commercial genetic testing today, this example highlights the potential of functional common variants, located throughout the genome, to contribute to nonchannelopathic genetic heart disorders and reinforces the danger of overlooking the potential clinical relevance of common variants on the basis of MAF alone. In addition, common functional nonsynonymous variants in familial hypercholesterolemia-susceptibility genes, most notably p.Gly116Ser-LDLR present in ≈10% of Inuit individuals, 67 strongly influence plasma low-density lipoprotein levels or result in a nonclassical familial hypercholesterolemia phenotype. Similar to the African-specific p.Ser1103Tyr-SCN5A LQTS functional risk allele, a strict application of the 2015 ACMG/AMP guidelines would classify the Inuit-specific p.Gly116Ser-LDLR familial hypercholesterolemia functional risk allele as benign on the basis of MAF alone.
As additional Mendelian genome-wide association studies and large-scale genetic modifier studies are undertaken, our understanding of the contribution of common variants to the genetic architecture of Mendelian genetic heart disorders is anticipated to grow. When coupled with the ongoing shift from disease-specific genetic testing to relatively nonspecific pancardiac gene panels and clinical whole-exome/genome sequencing, the likelihood that a common but potentially clinically relevant genetic variant in Mendelian disease-susceptibility genes is encountered is expected to increase exponentially. As such, these examples in the cardiac channelopathies, cardiomyopathies, and familial hypercholesterolemia serve to further underscore the acute need to develop and implement mechanisms to delineate so-called risk alleles in Mendelian disease-susceptibility genes from variants that are truly benign or of uncertain significance.
CONCLUSIONS
Although the current ACMG/AMP variant classification and reporting standards provide a solid foundation, by general nature these guidelines were not intended, nor Light gray boxes denote basic considerations pertaining to the initiation of genetic testing. Light orange boxes denote key steps in the classification of rare, rare common, and common genetic variants based on existing American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology (AMP) guidelines highlighting how existing benign and pathogenic criteria can be utilized to identify potential rare common conditional variants. Green boxes denote basic considerations pertaining to the identification of a rare variant of unknown/uncertain significance that currently lacks sufficient evidence to classify as either benign or pathogenic. OR indicates odds ratio. *Given a substantial clinical and genetic overlap, evidence supporting a role in congenital and acquired long QT syndrome (LQTS) should be considered when classifying potential LQTS risk alleles. †Variant designations that merit inclusion on LQTS genetic testing reports under distinct primary findings (pathogenic and variants of uncertain significance) or "Other Reportable" (functional risk alleles) categories. Adapted from Giudicessi et al 64 with permission. Copyright © 2017, Elsevier.
should they be presumed, to account for the intricacies and idiosyncrasies associated with specific disorders. As illustrated in this white paper, the application of a one-size-fits-all approach to variant interpretation has likely resulted in genetic tests that suboptimally reflect a patient's true underlying genetic risk of potentially fatal cardiac arrhythmias. Ultimately, the general ACMG/AMP framework needs to be adapted and tailored to fit LQTS and other genetic heart disorders through the development of expert consensus variant guidelines regarding the classification and reporting of rare and common genetic variants. However, until such documents can be drafted and thoroughly vetted, the risk allele and functional risk allele designations put forward in this white paper may serve as the best, albeit imperfect, stop-gap measure designed to ensure that ordering healthcare professionals are informed of common variants such as p.Ser1103Tyr-SCN5A and p.Asp85Asn-KCNE1 encountered during disease-specific, pancardiac, and clinical whole-exome genetic testing and afforded every opportunity to institute the simple interventions (ie, avoidance of QTc-prolonging medications [www.crediblemeds.org], 65 judicious use of antipyretics, potassium supplementation, etc) needed to mitigate the small but increased risk for sudden death these variants confer.
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